Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.

The aim of this investigation was to screen and understand the product variability due to important factors affecting the characteristics CyA-PLGA nanoparticles prepared by O/W emulsification-solvent evaporation method. Independent variables studied were cyclosporine A (CyA) (X(1)), PLGA (X(2)), and emulsifier concentration namely SLS (X(3)), stirring rate (X(4)), type of organic solvent employed (chloroform or dichloromethane, X(5)) and organic to aqueous phase ratio (X(6)). The nanoparticles properties considered were encapsulation efficiency (Y(1)), mean particle size (Y(2)), zeta potential (Y(3)), burst effect (Y(4)) and dissolution efficiency (Y(5)). The statistical analysis of the results allowed determining the most influent factors. The nanoparticles were characterized by scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray powder diffraction (XRD) and Fourier transform infrared (FTIR) spectroscopy. The factors combination showed variability of entrapment efficiency (Y(1)), mean particle size (Y(2)) and zeta potential (Y(3)) from 10.17% to 93.01%, 41.60 to 372.80 nm and 29.60 to 34.90 mV, respectively. Initially, nanoparticles showed burst effect followed by sustained release during the 7-day in vitro release study period. The dissolution efficiency (Y(5)) varied from 52.67% to 84.11%. The nanoparticles revealed Higuchi release pattern and release occurred by coupling of diffusion and erosion. In conclusion, this study revealed the potential of QbD in understanding the effect of formulation and process variables on the characteristics on CyA-PLGA nanoparticles.

[1]  G. Akman-Demir,et al.  Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? , 2008, Clinical and experimental rheumatology.

[2]  D. Rodríguez‐Puyol,et al.  Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  Zhanju Liu,et al.  Current strategies for the treatment of ulcerative colitis. , 2009, Recent patents on inflammation & allergy drug discovery.

[4]  K. A. Khan The concept of dissolution efficiency , 1975, The Journal of pharmacy and pharmacology.

[5]  Quantitative determination of amorphous cyclosporine in crystalline cyclosporine samples by Fourier transform infrared spectroscopy. , 2006, Journal of pharmaceutical sciences.

[6]  K. Järvinen,et al.  In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. , 2006, International journal of pharmaceutics.

[7]  N A Peppas,et al.  Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). , 2001, Advanced drug delivery reviews.

[8]  H. Takeuchi,et al.  Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[9]  M. R. Kumar,et al.  PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Tao Zhang,et al.  Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[11]  M. Vert,et al.  Preparation and degradation of surfactant-free PLAGA microspheres , 1995 .

[12]  Arash Akhavan,et al.  Atopic dermatitis: systemic immunosuppressive therapy. , 2008, Seminars in cutaneous medicine and surgery.

[13]  T. Higuchi MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES. , 1963, Journal of pharmaceutical sciences.

[14]  N. Yoshimura,et al.  Dialysis and renal transplantation as renal replacement therapy for end-stage renal failure, with special reference to the ethical problems of living renal donation , 2001 .

[15]  Steven P Schwendeman,et al.  Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. , 2008, International journal of pharmaceutics.

[16]  G. V. Patil,et al.  Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  R. Jalil,et al.  Microencapsulation using poly(L-lactic acid). I: Microcapsule properties affected by the preparative technique. , 1989, Journal of microencapsulation.

[18]  R. Plackett,et al.  THE DESIGN OF OPTIMUM MULTIFACTORIAL EXPERIMENTS , 1946 .

[19]  Mohamed H. El-Shabouri,et al.  Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. , 2002, International journal of pharmaceutics.

[20]  A. Abdul-Fattah,et al.  Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. , 2003, Journal of pharmaceutical sciences.

[21]  S. Chimenti,et al.  Efficacy of Short-Term Cyclosporine Treatment to Control Psoriasis-Related Events during Efalizumab Therapy , 2008, Dermatology.

[22]  M. Blanco-Prieto,et al.  Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. , 1997, Advanced drug delivery reviews.

[23]  R. Venkataramanan,et al.  Clinical Pharmacokinetics of Cyclosporin , 1986, Clinical pharmacokinetics.

[24]  R. Reithmeier,et al.  Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A. , 1995, The American journal of physiology.

[25]  Yi Yan Yang,et al.  Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. , 2001, Biomaterials.

[26]  R. Kryscio,et al.  Dosing and safety of cyclosporine in patients with severe brain injury. , 2008, Journal of neurosurgery.

[27]  Qing Yang,et al.  Biodegradable Progesterone Microsphere Delivery System for Osteoporosis Therapy , 2000, Drug development and industrial pharmacy.

[28]  A. Fahr Cyclosporin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.

[29]  F. Ahmad,et al.  Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  F. Hirayama,et al.  Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution. , 1999, Journal of pharmaceutical sciences.

[31]  Yi Yan Yang,et al.  Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method , 2000 .

[32]  A. Czogalla,et al.  Oral cyclosporine A - the current picture of its liposomal and other delivery systems , 2008, Cellular & Molecular Biology Letters.

[33]  P. Emery,et al.  Clinical Use of Cyclosporin in Rheumatoid Arthritis , 2012, Drugs.

[34]  R. Yousuf,et al.  Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: a technical note. , 2006, AAPS PharmSciTech.

[35]  C. Chaw,et al.  Ciclosporin-loaded poly(lactide) microparticles: Effect of TPGS , 2009, Journal of microencapsulation.

[36]  R. Dahlqvist,et al.  Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing , 2004, European Journal of Clinical Pharmacology.

[37]  S. Davis,et al.  The preparation and characterisation of poly(lactide-co-glycolide) microparticles. I: Oil-in-water emulsion solvent evaporation , 1991 .